VisionGate is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia.
VisionGate is developing a revolutionary non-invasive test for the early detection of lung cancer, using its automated 3D cell imaging platform.
VisionGate was founded in 2001 by Alan Nelson. The company is headquartered in Phoenix, Arizona, with an office in Nebraska.
VisionGate has a comprehensive offering that includes both a diagnostic to accurately detect lung cancer across all stages as well as a chemoprevention drug to treat dysplasia, or pre-cancerous cells, of the lung.
VisionGate's LuCED, a diagnostic test, is a non-invasive, physician-ordered, take-home sputum test with exquisite sensitivity and specificity across all lung cancer types and stages. LuCED is processed on its proprietary, fully automated 3D cell imaging platform, the Cell-CT, which captures 1,000 cell images per second and measures 594 cell features.
VisionGate's lead investigative pharmaceutical product iloprost, an oral prostacyclin analog, has progressed through an NCI-sponsored Phase 2 clinical trial. Iloprost is a potential first-in-class lung cancer prevention drug in clinical development to treat former smokers for the reduction of moderate to severe bronchial dysplasia as measured by the LuCED® lung test.
VisionGate is backed by Trinnovate Ventures, GreyBird Ventures, National Institutes of Health, Qualifying Therapeutic Discovery Project and others. The company raised $36.6M in a latest venture round on Dec 23, 2019. This new round brings VisionGate's total funding to $58.2M to date.